
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Lead Product(s) : IPH5301,Trastuzumab,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Innate Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IPH5301 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 03, 2021
Lead Product(s) : IPH5301,Trastuzumab,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Innate Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
